

ICMJE DISCLOSURE FORM

Date: 25.04.2023

Your Name: Edyta Maria Urbanska

Manuscript Title: Choice of first-line ALK TKI treatment based on the results of a systematic review and network meta-analysis.

Manuscript number (if known): PCM-23-11

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Janssen, lectures	
		Amgen, lectures	
		AstraZeneca, lectures	
		Novartis, lectures	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	AstraZeneca	Upcoming participation in IASLC WCLC 2023, Singapore
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Roche, Advisory Board	
		Takeda, Advisory Board	
		Pfizer, Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

No support for the present manuscript

Honoraria for lectures from Amgen, AstraZeneca, Janssen, Novartis

Support from AstraZeneca for participation at IASLC WCLC 2023, Singapore

.. Advisory Board – Pfizer, Roche, Takeda

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.